Biota Pharmaceuticals, Inc. to Present at the 8th Annual JMP Securities
ATLANTA, June 27, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc.
(Nasdaq:BOTA) today announced that its President and Chief Executive Officer,
Russell H. Plumb, will present an update on the company at the 8th Annual JMP
Securities Healthcare Conference at 2:30 p.m. EDT, July 10, 2013, at The St.
Regis Hotel in New York City.
The presentation will be webcast live and may be accessed through the Investor
Relations' Events and Presentations section on Biota's website at
www.biotapharma.com. Please go to the website at least 15 minutes prior to the
event to register, download and install any necessary audio/video software. An
archived replay will also be available for 90 days following the live
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
discovery and development of products to prevent and treat serious and
potentially life-threatening infectious diseases. The Company currently has
two Phase 2 clinical-stage product candidates in development: Laninamivir
octanoate, which the Company is developing for the treatment of influenza A
and B infections in the U.S. through a contract with the U.S. Office of
Biomedical Advanced Research and Development Authority (BARDA) to provide up
to $231 million in financial support to complete its clinical development; and
vapendavir, a potent, oral broad-spectrum capsid inhibitor of human
rhinovirus. In addition to these clinical-stage programs, the Company has
preclinical programs focused on developing treatments for respiratory
syncytial virus and gram-negative, multi-drug resistant bacterial infections.
For additional information about the Company, please visit
CONTACT: Russell H. Plumb
Chief Executive Officer
Blueprint Life Science Group
Biota Pharmaceuticals, Inc
Press spacebar to pause and continue. Press esc to stop.